Compare ASLE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASLE | AKBA |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.5M | 248.3M |
| IPO Year | 2018 | 2014 |
| Metric | ASLE | AKBA |
|---|---|---|
| Price | $4.60 | $0.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $6.50 | $3.92 |
| AVG Volume (30 Days) | 392.3K | ★ 8.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.64 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,286,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.54 | $0.54 |
| 52 Week High | $7.93 | $1.89 |
| Indicator | ASLE | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 25.15 |
| Support Level | $4.54 | N/A |
| Resistance Level | $5.14 | $1.54 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 17.31 | 9.73 |
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.